-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care with Team-Based Diagnosis and Treatment for Lower- and Higher-Risk Disease

Sponsor: Bristol Myers Squibb, Geron Corporation, Karyopharm Therapeutics, and Novartis Pharmaceuticals
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Workforce, Diseases, Therapies, Adverse Events, Biological Processes
Friday, December 8, 2023: 7:00 AM-10:00 AM
Ballroom 20CD (San Diego Convention Center)
Maria Diez-Campelo, MD, PhD, University Hospital of Salamanca
Diez-Campelo: BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Advisory board fees; Gilead Sciences: Other: Travel expense reimbursement; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees.
Rory M. Shallis, MD, Section of Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center and Aditi Shastri, MD, Albert Einstein College of Medicine
Shallis: Bristol Myers Squibb: Consultancy; Curio Science: Consultancy; Gilead Sciences: Consultancy; Servier: Consultancy; Rigel: Consultancy. Shastri: Kymera Therapeutics: Honoraria, Research Funding; Gilead Sciences: Honoraria; Rigel Pharmaceuticals: Honoraria; Janssen Pharmaceuticals, Inc.: Consultancy, Honoraria.
On Demand program will be available here December 13, 2023.

This CME/MOC activity is provided by Penn State College of Medicine and developed with our educational partner, PVI, PeerView Institute for Medical Education.

This activity is supported through educational grants from Astex Pharmaceuticals, Inc., Bristol Myers Squibb, Geron, Karyopharm Therapeutics, and Novartis Pharmaceuticals Corporation.

The baseline assessment and subsequent management of myelodysplastic syndromes (MDS) is increasingly personalized to address the unique biology of this disorder and the well-recognized unmet medical needs of patients. PeerView’s unique Seminars & Tumor Board live event will explore this new therapeutic territory by pairing compelling case scenarios with collaborative real-world tumor board decision-making and, in doing so, provide expert guidance on the practice-changing evidence driving precision medicine in LR- and HR-MDS. Throughout, expert faculty will offer insights on 1) team-based methods for patient assessment, diagnosis, and prognostic assessment; 2) the challenges of characterizing and designing treatment plans for LR- and HR-MDS; 3) updated evidence supporting the use of innovative therapies for the 1L management of MDS anemia, ESA-refractory patients, and individuals presenting with high-risk mutations or cytogenetics (including TP53 mutations); and 4) practical strategies for effective delivery of care.